在扩散性皮肤全身性硬化症中的贝卢莫苏迪尔:一个随机的,双盲的,开放的标签扩展,安慰剂控制的,第二阶段研究
Lorinda Chung1,2, Richard M Silver3, Virginia Steen4
1Department of Medicine and Dermatology, Stanford University School of Medicine, Stanford, California, USA.
Rheumatology (Oxford, England)
|March 15, 2025
概括
贝卢莫苏迪尔在扩散性皮肤性全身性硬化症 (dcSSc) 患者中没有显示出有效性,尽管耐受性很好. 途径分析支持了它的作用机制,趋势是纤维化生物标志物减少.
科学领域:
- 风湿病学和免疫学
- 药理学和治疗学 药理学和治疗学
- 皮肤病学 皮肤病学
背景情况:
- 扩散性皮肤全身性硬化症 (dcSSc) 是一种严重的自身免疫性疾病,其特征是广泛的皮肤加厚和内脏器官受影响.
- 目前对dcSSc的治疗方法有效性有限,副作用很大.
- 一种ROCK2抑制剂贝卢莫苏迪尔正在研究其在自身免疫性疾病中的潜在免疫调节和抗纤维性作用.
研究的目的:
- 评估dcSSc.患者中 belumosudil 的疗效,安全性和药理动力学.
- 评估 belumosudil 对 CRISS 评分的影响,这是系统性硬化症严重程度的衡量标准.
- 通过RNA测序和生物标志物分析,探索 belumosudil 的作用机制.
主要方法:
- 一个随机的,双盲的,安慰剂对照试验与一个开放的标签扩展.
- 患有dcSSc的患者接受了28周的 belumosudil (200 mg QD或BID) 或安慰剂.
- 主要终点是24周的CRISS得分≥0.60,次要终点包括安全性和药理动力学标记.
主要成果:
- 该研究提前终止;目标招生人数没有达到.
- 与安慰剂相比,贝卢莫苏迪尔对于主要终点 (CRISS评分) 没有显示出显著的疗效信号.
- 贝卢莫苏迪尔在各组中耐受性良好,安全性概况相似. RNA测序显示FOXP3上调和STAT3,IL23A,TGF-β下调,支持药物的机制. 观察到纤维化生物标志物减少的趋势.
结论:
- 贝卢莫苏迪尔在这个dcSSc患者队列中没有显示出可检测的疗效.
- 药理动力学分析证实了 belumosudil 的作用机制.
- 纤维化生物标志物减少的趋势表明,潜在的治疗益处需要进一步研究.
相关概念视频
Blind Procedures
10.8K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.8K
Modified-Release Drug Delivery Systems: Stimuli-Activated
184
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
184
Multiple Sclerosis l: Introduction
31
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
31
Huntington Disease l: Introduction
166
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
166


